Explain this page
Arphra AIPlain-English read on Merck & Co., Inc.’s valuationInsider signal · 90d
Balanced
Bought
$0
Sold
$0
Txns
0
Over the trailing 90 days insiders are balanced — $0 bought against $0 sold across 0 open-market Form-4 transactions. Much insider selling is scheduled (10b5-1); read the asymmetry, not any single print.
Open-market Form 4
· insider_tradesInsider transactions · last 365d
Net −$32.2M0 buys
| Insider | Role | Type | Shares | Value | Date |
|---|---|---|---|---|---|
| Guindo Chirfi | officer: Chief Marketing Officer | Sell | −10,000 | $1.2M | Feb 12, 2026 |
| Li Dean Y | officer: Executive VP & President, MRL | Sell | −10,235 | $1.2M | Feb 10, 2026 |
| Guindo Chirfi | officer: Chief Marketing Officer | Sell | −10,000 | $1.2M | Feb 09, 2026 |
| Zachary Jennifer | officer: EVP, General Counsel | Sell | −38,835 | $4.6M | Feb 09, 2026 |
| Oosthuizen Johannes Jacobus | officer: President, U.S. Market | Sell | −15,000 | $1.8M | Feb 06, 2026 |
| DeLuca Richard R. | officer: EVP&Pres, Merck Animal Heallth | Sell | −37,685 | $4.6M | Feb 06, 2026 |
| Williams David Michael | officer: EVP,Chief Info&Digital Officer | Sell | −5,000 | $609.5K | Feb 06, 2026 |
| Guindo Chirfi | officer: Chief Marketing Officer | Sell | −20,000 | $2.4M | Feb 05, 2026 |
| Smart Dalton E. III | officer: SVP Fin. - Global Controller | Sell | −4,000 | $478.7K | Feb 04, 2026 |
| Davis Robert M | director, officer: Chairman, CEO & President | Sell | −32,462 | $3.8M | Feb 04, 2026 |
| Li Dean Y | officer: Executive VP & President, MRL | Sell | −15,087 | $1.8M | Feb 04, 2026 |
| Litchfield Caroline | officer: EVP & CFO | Sell | −41,997 | $5.0M | Feb 04, 2026 |
| Smart Dalton E. III | officer: SVP Fin. - Global Controller | Sell | −2,400 | $287.2K | Feb 04, 2026 |
| Davis Robert M | director, officer: Chairman, CEO & President | Sell | −14,972 | $1.8M | Feb 04, 2026 |
Transaction mix · 365d
100%
Sells16 · $32.2M
Buys0 · $0
Top sellers · 365d
Davis Robert M · director, officer: Chairman, CEO & President−$5.6M
Litchfield Caroline · officer: EVP & CFO−$5.0M
Guindo Chirfi · officer: Chief Marketing Officer−$4.8M
Transactions
16
0 buys · 16 sells
Bought
$0
Open market
Sold
$32.18M
Open market
Net flow
−$32.18M
Buys − sells
Transactions
| Insider | Role | Action | Shares | Price | Value | Trade date | Filing |
|---|---|---|---|---|---|---|---|
| Guindo Chirfi | officer: Chief Marketing Officer | Sell | 10,000 | $121.46 | $1.21M | Feb 12, 2026 | Feb 12, 2026 |
| Li Dean Y | officer: Executive VP & President, MRL | Sell | 10,235 | $117.52 | $1.2M | Feb 10, 2026 | Feb 10, 2026 |
| Guindo Chirfi | officer: Chief Marketing Officer | Sell | 10,000 | $118.41 | $1.18M | Feb 09, 2026 | Feb 09, 2026 |
| Zachary Jennifer | officer: EVP, General Counsel | Sell | 38,835 | $119.15 | $4.63M | Feb 09, 2026 | Feb 09, 2026 |
| Oosthuizen Johannes Jacobus | officer: President, U.S. Market | Sell | 15,000 | $121.87 | $1.83M | Feb 06, 2026 | Feb 06, 2026 |
| DeLuca Richard R. | officer: EVP&Pres, Merck Animal Heallth | Sell | 37,685 | $120.92 | $4.56M | Feb 06, 2026 | Feb 06, 2026 |
| Williams David Michael | officer: EVP,Chief Info&Digital Officer | Sell | 5,000 | $121.91 | $609.53K | Feb 06, 2026 | Feb 06, 2026 |
| Guindo Chirfi | officer: Chief Marketing Officer | Sell | 20,000 | $121.88 | $2.44M | Feb 05, 2026 | Feb 06, 2026 |
| Smart Dalton E. III | officer: SVP Fin. - Global Controller | Sell | 4,000 | $119.68 | $478.7K | Feb 04, 2026 | Feb 06, 2026 |
| Davis Robert M | director, officer: Chairman, CEO & President | Sell | 32,462 | $118.35 | $3.84M | Feb 04, 2026 | Feb 06, 2026 |
| Li Dean Y | officer: Executive VP & President, MRL | Sell | 15,087 | $118.77 | $1.79M | Feb 04, 2026 | Feb 06, 2026 |
| Litchfield Caroline | officer: EVP & CFO | Sell | 41,997 | $119.61 | $5.02M | Feb 04, 2026 | Feb 06, 2026 |
| Smart Dalton E. III | officer: SVP Fin. - Global Controller | Sell | 2,400 | $119.68 | $287.22K | Feb 04, 2026 | Feb 06, 2026 |
| Davis Robert M | director, officer: Chairman, CEO & President | Sell | 14,972 | $117.38 | $1.76M | Feb 04, 2026 | Feb 06, 2026 |
| Downing Cristal N | officer: Chief Comm. & Public Afrs Ofcr | Sell | 7,085 | $87.00 | $616.4K | Nov 10, 2025 | Nov 12, 2025 |
| Williams David Michael | officer: EVP,Chief Info&Digital Officer | Sell | 8,614 | $83.59 | $720.04K | Nov 03, 2025 | Nov 04, 2025 |
By insider
- Davis Robert M−$5.6Mdirector, officer: Chairman, CEO & President0B · 2S
- Litchfield Caroline−$5.02Mofficer: EVP & CFO0B · 1S
- Guindo Chirfi−$4.84Mofficer: Chief Marketing Officer0B · 3S
- Zachary Jennifer−$4.63Mofficer: EVP, General Counsel0B · 1S
- DeLuca Richard R.−$4.56Mofficer: EVP&Pres, Merck Animal Heallth0B · 1S
- Li Dean Y−$2.99Mofficer: Executive VP & President, MRL0B · 2S
- Oosthuizen Johannes Jacobus−$1.83Mofficer: President, U.S. Market0B · 1S
- Williams David Michael−$1.33Mofficer: EVP,Chief Info&Digital Officer0B · 2S
- Smart Dalton E. III−$765.92Kofficer: SVP Fin. - Global Controller0B · 2S
- Downing Cristal N−$616.4Kofficer: Chief Comm. & Public Afrs Ofcr0B · 1S
Beneficial ownership filings
Schedule 13D / 13G — investors holding more than 5% of MRK-LN.
DB · acquisition_ownership65
| Filed | Reporting person | Form | Type | Aggregate owned | % Class | Sole voting | Shared voting | Citizenship | |
|---|---|---|---|---|---|---|---|---|---|
| Apr 30, 2026 | Vanguard Capital Management | — | IA | — | +7.53% | 0 | 0 | PENNSYLVANIA | SEC → |
| Mar 27, 2026 | The Vanguard Group | — | IA | — | 0.00% | 0 | 0 | PENNSYLVANIA | SEC → |
| Mar 06, 2025 | The Vanguard Group | — | IA | — | +10.02% | 12.51M | 12.51M | PENNSYLVANIA | SEC → |
| Feb 03, 2025 | Merck & Co., Inc. | — | HC, CO | — | +19.96% | 63M | 63M | NEW JERSEY | SEC → |
| Jan 23, 2024 | Merck & Co., Inc. | — | HC, CO | — | +11.40% | 0 | 4.6M | New Jersey | SEC → |
| Jan 23, 2024 | Merck Sharp & Dohme LLC | — | OO | — | +11.40% | 0 | 4.6M | New Jersey | SEC → |
| Jan 23, 2024 | Merck Global Health Innovation Fund, LLC | — | OO | — | +11.40% | 0 | 4.6M | New Jersey | SEC → |
| Feb 02, 2022 | Merck & Co., Inc. | — | HC, CO | — | +6.60% | 0 | 12.15M | New Jersey | SEC → |
| Feb 02, 2022 | Merck Sharp & Dohme Corp. | — | CO | — | +6.60% | 0 | 12.15M | New Jersey | SEC → |
| Feb 01, 2022 | (1) BlackRock, Inc. | — | HC | — | +7.80% | 171.96M | 0 | Delaware | SEC → |
| Mar 04, 2021 | MERCK & CO., INC. | — | HC, CO | — | +39.99% | 0 | 11.78M | — | SEC → |
| Mar 04, 2021 | MERCK SHARP & DOHME CORP. | — | HC, CO | — | +39.99% | 0 | 11.78M | — | SEC → |
| Mar 04, 2021 | PANAMA MERGER SUB, INC. | — | CO | — | +39.99% | 0 | 11.78M | — | SEC → |
| Jan 04, 2021 | Merck Sharp & Dohme Corp. | — | CO | — | +5.20% | 0 | 527K | New Jersey | SEC → |
| Jan 04, 2021 | Merck & Co., Inc. | — | HC, CO | — | +5.20% | 0 | 527K | New Jersey | SEC → |
| Feb 12, 2020 | The Vanguard Group - 23-1945930 | — | IA | — | +8.26% | 3.94M | 747.59K | Pennsylvania | SEC → |
| Dec 16, 2019 | MERCK SHARP & DOHME CORP. | — | HC, CO | — | +12.60% | 0 | 17.48M | NEW JERSEY | SEC → |
| Dec 16, 2019 | MERCK & CO., INC. | — | HC, CO | — | +12.60% | 0 | 17.48M | NEW JERSEY | SEC → |
| Dec 16, 2019 | ARGON MERGER SUB, INC. | — | CO | — | +12.60% | 0 | 17.48M | DELAWARE | SEC → |
| Apr 09, 2019 | Merck & Co., Inc. | — | HC | — | +19.90% | 12.96M | 0 | New Jersey | SEC → |
| Apr 09, 2019 | Merck Sharp & Dohme Corp. | — | CO | — | +19.90% | 12.96M | 0 | New Jersey | SEC → |
| Feb 14, 2019 | Merck Sharp & Dohme Corp. | — | CO | — | +5.10% | 3.55M | 0 | New Jersey | SEC → |
| Feb 14, 2019 | MRL Ventures Fund LLC | — | OO | — | +5.10% | 3.55M | 0 | Delaware | SEC → |
| Feb 14, 2019 | Merck & Co., Inc. | — | HC | — | +5.10% | 3.55M | 0 | New Jersey | SEC → |
| Feb 06, 2019 | (1) BlackRock, Inc. | — | HC | — | +7.50% | 170.07M | 0 | Delaware | SEC → |
| Oct 04, 2018 | Merck & Co., Inc. | — | CO | — | +11.90% | 2.72M | 0 | New Jersey | SEC → |
| Oct 04, 2018 | Merck Sharp & Dohme Corp. | — | CO | — | +11.90% | 2.72M | 0 | New Jersey | SEC → |
| Feb 14, 2018 | Merck & Co., Inc. | — | HC | — | +5.41% | 1.24M | 0 | New Jersey | SEC → |
| Feb 14, 2018 | Merck Sharp & Dohme Corp. | — | CO | — | +5.41% | 1.24M | 0 | New Jersey | SEC → |
| Feb 13, 2018 | Merck Sharp & Dohme Research GmbH | — | FI | — | 0.00% | 0 | 0 | Switzerland | SEC → |
Showing 30 of 65 filings. All disclosures →
Top 10 holders · 8 quarters
13F position evolutionNo 13F history in
institutional_holders for MRK-LN.